兰索拉唑联合氟哌噻吨美利曲辛治疗功能性消化不良的疗效及价值评价(1)
【摘 要】目的：探讨兰索拉唑联合氟哌噻吨美利曲辛治疗功能性消化不良的疗效及价值。方法：入选研究对象均为我院2013年1月-2015年1月消化内科门诊患者，均确诊为功能性消化不良，共60例，随机分组，各组30例，对照组给予兰索拉唑肠溶片联合莫沙必利。观察组在对照组基础上联合氟哌噻吨美利曲辛。采用LDQ评量表评估患者消化不良的症状，对比两组患者治疗前后的症状变化；采用HAD评量表评估两组患者治疗前后的焦虑、抑郁情绪。结果：(1)组间对比，观察组治疗后LDQ评分、HAD评分以及治疗有效率明显优于对照组，P<0.05。结论：兰索拉唑联合氟哌噻吨美利曲辛治疗功能性消化不良的疗效显著，值得应用。
【关键词】兰索拉唑；氟哌噻吨美利曲辛；功能性消化不良
Abstract objective： to explore the curative effect and value of lansoprazole combined with fluoperthiazide in the treatment of functional dyspepsia. Methods： all the subjects included in the study were patients from the department of gastroenterology of our hospital from January 2013 to January 2015， all of whom were diagnosed as functional dyspepsia. A total of 60 cases were randomly divided into three groups， with 30 cases in each group. The control group was given lansoprazole enteric-coated tablets combined with moxabilli. The observation group was combined with fluoperthion meritracine on the basis of the control group. The symptoms of dyspepsia were evaluated by LDQ scale， and the changes of symptoms before and after treatment were compared between the two groups. Anxiety and depression before and after treatment were evaluated by the HAD scale. Results ：(1) after treatment， LDQ score， HAD score and treatment efficiency of the observation group were significantly better than those of the control group， P<0.05. Conclusion： lansoprazole combined with fluperazide is effective in the treatment of functional dyspepsia and is worthy of application.
Keywords： lansoprazole； Flupertiton melikoxine； Functional dyspepsia
【中圖分类号】R969.2 【文献标识码】B 【文章编号】1672-3783(2018)11-03--01
功能性消化不良(FD)是一种发病率较高的消化道疾病，在消化门诊疾病中占比高达50%[1]。其发病因素复杂，可涉及到胃肠道功能不良、内脏敏感、胃酸分泌过多、幽门螺杆菌、精神心理压力等因素。现如今，常规的治疗主要通过药物联合使用改善功能性消化不良的症状，常用的药物一般包括促动力药、质子泵抑制剂(PPI)。但是，许多研究表明常规方案疗效并不明显，需联合抗焦虑抑郁药与心理辅导治疗才可以提高疗效。本研究通过对我院功能性消化不良患者进行对照试验，探讨兰索拉唑联合氟哌噻吨美利曲辛治疗功能性消化不良的疗效及价值。现报道如下。
1 资料与方法
1.1 基本资料
入选研究对象均为我院2013年1月-2015年1月消化内科门诊患者，均确诊为功能性消化不良，共60例，与罗马III的功能性消化不良的诊断标准相符合。排除胃部器质性疾病、腹部手术史、肝病、胆道疾病、胰腺疾病、心脏病、肺部疾病、肾疾病、幽门螺杆菌感染等患者。同时，近1个月内停止使用对胃粘膜造成损伤的药物、可能造成消化不良的药物、抗菌药和其他影响消化系统功能的药物。全部患者均签署知情同意书，本研究已经通过医院伦理委员会的审核和批准。随机分组，各组30例，观察组男15例，女15例，年龄23-63岁，平均年龄为41.50±3.60岁；对照组男18例，女12例，年龄23-63岁，平均年龄为41.50±3.55岁。两组患者基本资料比较差异无统计学意义，P>0.05。
1.2 方法
对照组：给予兰索拉唑肠溶片(国药准字H20067606，江苏康缘药业股份有限公司，15mg/次，1次/d，早餐前口服)，或联合莫沙必利(国药准字H20090158，亚宝药业集团股份有限公司，5mg/次，3次/d，口服)，疗程1个月。
观察组：在兰索拉唑肠溶片(15mg/次，1次/d，早餐前口服)+莫沙必利(5mg/次，3次/d，口服)前提，联合氟哌噻吨美利曲辛(H20130126，丹麦灵北制药有限公司10.5mg/次，2次/d，口服)，疗程1个月。, 百拇医药(王康平)
【关键词】兰索拉唑；氟哌噻吨美利曲辛；功能性消化不良
Abstract objective： to explore the curative effect and value of lansoprazole combined with fluoperthiazide in the treatment of functional dyspepsia. Methods： all the subjects included in the study were patients from the department of gastroenterology of our hospital from January 2013 to January 2015， all of whom were diagnosed as functional dyspepsia. A total of 60 cases were randomly divided into three groups， with 30 cases in each group. The control group was given lansoprazole enteric-coated tablets combined with moxabilli. The observation group was combined with fluoperthion meritracine on the basis of the control group. The symptoms of dyspepsia were evaluated by LDQ scale， and the changes of symptoms before and after treatment were compared between the two groups. Anxiety and depression before and after treatment were evaluated by the HAD scale. Results ：(1) after treatment， LDQ score， HAD score and treatment efficiency of the observation group were significantly better than those of the control group， P<0.05. Conclusion： lansoprazole combined with fluperazide is effective in the treatment of functional dyspepsia and is worthy of application.
Keywords： lansoprazole； Flupertiton melikoxine； Functional dyspepsia
【中圖分类号】R969.2 【文献标识码】B 【文章编号】1672-3783(2018)11-03--01
功能性消化不良(FD)是一种发病率较高的消化道疾病，在消化门诊疾病中占比高达50%[1]。其发病因素复杂，可涉及到胃肠道功能不良、内脏敏感、胃酸分泌过多、幽门螺杆菌、精神心理压力等因素。现如今，常规的治疗主要通过药物联合使用改善功能性消化不良的症状，常用的药物一般包括促动力药、质子泵抑制剂(PPI)。但是，许多研究表明常规方案疗效并不明显，需联合抗焦虑抑郁药与心理辅导治疗才可以提高疗效。本研究通过对我院功能性消化不良患者进行对照试验，探讨兰索拉唑联合氟哌噻吨美利曲辛治疗功能性消化不良的疗效及价值。现报道如下。
1 资料与方法
1.1 基本资料
入选研究对象均为我院2013年1月-2015年1月消化内科门诊患者，均确诊为功能性消化不良，共60例，与罗马III的功能性消化不良的诊断标准相符合。排除胃部器质性疾病、腹部手术史、肝病、胆道疾病、胰腺疾病、心脏病、肺部疾病、肾疾病、幽门螺杆菌感染等患者。同时，近1个月内停止使用对胃粘膜造成损伤的药物、可能造成消化不良的药物、抗菌药和其他影响消化系统功能的药物。全部患者均签署知情同意书，本研究已经通过医院伦理委员会的审核和批准。随机分组，各组30例，观察组男15例，女15例，年龄23-63岁，平均年龄为41.50±3.60岁；对照组男18例，女12例，年龄23-63岁，平均年龄为41.50±3.55岁。两组患者基本资料比较差异无统计学意义，P>0.05。
1.2 方法
对照组：给予兰索拉唑肠溶片(国药准字H20067606，江苏康缘药业股份有限公司，15mg/次，1次/d，早餐前口服)，或联合莫沙必利(国药准字H20090158，亚宝药业集团股份有限公司，5mg/次，3次/d，口服)，疗程1个月。
观察组：在兰索拉唑肠溶片(15mg/次，1次/d，早餐前口服)+莫沙必利(5mg/次，3次/d，口服)前提，联合氟哌噻吨美利曲辛(H20130126，丹麦灵北制药有限公司10.5mg/次，2次/d，口服)，疗程1个月。, 百拇医药(王康平)